New CBD Trials in Epileptic Patients Leads to Promising Results

New CBD Trials in Epileptic Patients Leads to Promising Results

May 16, 2017

At The American Epilepsy Society’s annual meeting, held on December 7, 2015 in Philadelphia it expressed opportunistic research concerning the use of hemp extract known as CBD (cannabidiol). CBD is a non-psychoactive extract from the hemp plant. This non-psychoactive extract does not alter one's mood, consciousness or perception.  Although this clinical research is anecdotal, the results were positive in most patients with debilitating seizures. Such forms of  these treatment-resistant disorders include Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS).    

GW Pharmaceutical’s conducted a study to administer Epidiolex (cannabidiol) to 261 patients. Epidiolex is an investigational drug and has not yet been approved for use by the FDA.

The experimental drug was introduced to the patient's current AED (anti-epileptic drugs) treatments and given in gradual amounts while increasing doses during the 12 week study.

Here are their results concluding the 12 week study:

  • 45% of the participants frequency in seizures were reduced
  • 47% of the participants had a considerable reduction of seizures
  • 9% were seizure free
  • 62% of DS patients experienced a reduction of seizures
  • 13% of DS patients were seizure free
  • 71% of LGS patients experienced a reduction of atonic seizures
  • 10% experienced adverse effects of somnolence, diarrhea and fatigue which led to discontinuation in four percent of patients.
  • 34% reported serious adverse events of which five percent were considered treatment related  
  • 12% withdrew due to lack of efficacy

Lead author Orrin Devinsky, M.D., of New York University Langone Medical Center’s Comprehensive Epilepsy Center said:

"We are pleased to report these promising data on significant numbers of children, These data reinforce and support the safety and efficacy we have shared in previous studies. Most importantly it is providing hope to the children and their families who have been living with debilitating seizures. These results are from an uncontrolled study. Further study is needed before results can be confirmed. Randomized controlled studies are now underway to help us better understand the effectiveness of the drug. As a practitioner, I have had families move to Colorado, and many tried multiple different products, As a doctor, I often don’t feel like I know which of many factors is contributing to a patient doing better or worse. We absolutely need rigorous, scientific data on this. We very much look forward to the results from these studies during 2016."

For more than 75 years the AES has provided a forum of medical & scientific members whose goal is the clinical care and research for people with epilepsy. Epilepsy and seizures affect three million Americans of all ages. The AES urges the Federal DEA to review Marijuana as a schedule 1 drug, as do I.

 

Summary and opinion by Ronald Pires. Check the full article here.


Leave a comment

Comments will be approved before showing up.


Also in Newsstand

Minorities needed in the Cannabis Lime-Light
Minorities needed in the Cannabis Lime-Light

June 22, 2017

From Cheech and Chong to Snoop Dogg, minorities have been the face and voice of the cannabis movement. Minority public figures often embraced the plant at a time it was most stigmatized and criminalized. Now, America seems to be changing its cannabis’ tune and more socially accepting of pot. With new cannabis legislation, decriminalization, and business opportunities to start; some are questioning minority representation in the industry, and why black farmers are left without a plot. In Maryland, not one of the fifteen cannabis growers chosen by the state for cultivation licenses is minority-owned. Only 1% of the marijuana dispensaries in the nation are black owned.

Read More

Gridiron Ganja: Did Marijuana Advocacy Lead to NFL Player’s Release?
Gridiron Ganja: Did Marijuana Advocacy Lead to NFL Player’s Release?

June 20, 2017

Baltimore Ravens offensive lineman Eugene Monroe won’t be on the next roster, and it may be for his advocacy for medical marijuana. Monroe’s January recovery from a shoulder injury inspired him to write about marijuana versus opioids, and donate $80,000 to medical marijuana researchers at both Johns Hopkins University and the University of Pennsylvania. His work, he tweeted, was all for his “brothers… the players that make up the team… our future health and wellness.”

Unfortunately, his offseason, offtopic efforts failed to impress the Ravens officials. In the days leading up to his release, attitudes from the organization led Monroe to wonder if his marijuana advocacy was to blame. Interestingly, his original questions were less about the drug, and more about overall NFL healthcare.

Read More

Workplace Drug Testing Is Going To Die Because of Legal Weed
Workplace Drug Testing Is Going To Die Because of Legal Weed

June 20, 2017

It is arguable that reviewing old drug testing policies is going to be a big trend in U.S. companies in the nearest future. If the weed is legal, and the job can be done safely under cannabis influence, why would an employer be concerned about marijuana consumption enough to spend money on drug testing? 

Current situation is creating a whole lot of consequences, like people easily cheating on drug tests by adding water to their urine, or other people making money on ‘weed detox sets’ that claim to free your system of cannabis traces in just three days. More than 93% test negative, but employers continue testing. In most cases, we just avoid working for companies that drug test employees. 

Read More